MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. 

About Cardiomyopathies

Heartbeats: A Conversation with The Hypertrophic Cardiomyopathy Experts

News & Events

02/04/16
A Small Molecule Inhibitor of Sarcomere Contractility Suppresses Hypertrophic Cardiomyopathy in Mice
Link

11/04/15
MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2015
Link

11/03/15
MyoKardia Announces Closing of Initial Public Offering
Link